Hrafnhildur Linnet Runolfsdottir1,2, Runolfur Palsson1,2, Inger M Sch Agustsdottir3, Olafur S Indridason2, Jennifer Li4, Myriam Dao5, Bertrand Knebelmann5,6,7, Dawn S Milliner8, Vidar O Edvardsson1,3. 1. Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland. 2. Internal Medicine and Rehabilitation Services, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland. 3. Children's Medical Center, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland. 4. Centre for Transplant and Renal Research, Westmead Institute for Medical Research, Sydney University, Sydney, Australia. 5. Department of Nephrology-Transplantation, Necker Hospital, APHP, Paris, France. 6. Paris Descartes University, Sorbonne Paris Cité, Paris, France. 7. Département Biologie cellulaire, INSERM U1151, Institut Necker Enfants Malades, Paris, France. 8. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: Adenine phosphoribosyltransferase (APRT) deficiency is a rare, hereditary cause of kidney stones and chronic kidney disease (CKD) which is characterized by 2,8-dihydroxyadenine renal parenchymal crystal deposition. The aim of this study was to examine outcomes of kidney transplantation in APRT deficiency patients. METHODS: Included were 13 patients in the APRT Deficiency Registry of the Rare Kidney Stone Consortium, 2 from Westmead Hospital in Sydney, Australia, and 2 from Necker Hospital in Paris, France. The CKD-EPI and CKiD equations were used to calculate glomerular filtration rate estimates. Allograft survival was analyzed employing the Kaplan-Meier method. The Wilcoxon-Mann-Whitney test was used to compare alllograft outcomes according to xanthine oxidoreductase (XOR) inhibitor treatment status at transplantation. RESULTS: Seventeen patients (9 females) received 22 kidney transplants. Age at first transplantation was 47.2 (14.9-67.0) years. Ten patients received XOR inhibitor therapy pretransplant (11 allografts), while 8 patients did not receive such treatment before transplantation (11 allografts). Two-year allograft survival was 91% and 55% in the 2 groups, respectively (P = 0.16). The median (range) estimated glomerular filtration rate at 2 years posttransplant was 61.3 (24.0-90.0) mL/min/1.73 m when XOR inhibitor therapy was initiated before transplantation, and 16.2 (10.0-39.0) mL/min/1.73 m (P = 0.009) when such treatment was not administered pretransplant. CONCLUSIONS: Kidney allograft outcomes are good in APRT deficiency patients beginning XOR inhibitor therapy pretransplant. Delay in such treatment is a major cause of premature graft loss in these patients. Increased awareness among clinicians is imperative, promoting early diagnosis of APRT deficiency and pharmacotherapy initiation before kidney transplantation.
BACKGROUND: Adenine phosphoribosyltransferase (APRT) deficiency is a rare, hereditary cause of kidney stones and chronic kidney disease (CKD) which is characterized by 2,8-dihydroxyadenine renal parenchymal crystal deposition. The aim of this study was to examine outcomes of kidney transplantation in APRT deficiency patients. METHODS: Included were 13 patients in the APRT Deficiency Registry of the Rare Kidney Stone Consortium, 2 from Westmead Hospital in Sydney, Australia, and 2 from Necker Hospital in Paris, France. The CKD-EPI and CKiD equations were used to calculate glomerular filtration rate estimates. Allograft survival was analyzed employing the Kaplan-Meier method. The Wilcoxon-Mann-Whitney test was used to compare alllograft outcomes according to xanthine oxidoreductase (XOR) inhibitor treatment status at transplantation. RESULTS: Seventeen patients (9 females) received 22 kidney transplants. Age at first transplantation was 47.2 (14.9-67.0) years. Ten patients received XOR inhibitor therapy pretransplant (11 allografts), while 8 patients did not receive such treatment before transplantation (11 allografts). Two-year allograft survival was 91% and 55% in the 2 groups, respectively (P = 0.16). The median (range) estimated glomerular filtration rate at 2 years posttransplant was 61.3 (24.0-90.0) mL/min/1.73 m when XOR inhibitor therapy was initiated before transplantation, and 16.2 (10.0-39.0) mL/min/1.73 m (P = 0.009) when such treatment was not administered pretransplant. CONCLUSIONS: Kidney allograft outcomes are good in APRT deficiency patients beginning XOR inhibitor therapy pretransplant. Delay in such treatment is a major cause of premature graft loss in these patients. Increased awareness among clinicians is imperative, promoting early diagnosis of APRT deficiency and pharmacotherapy initiation before kidney transplantation.
Authors: Hicham Skali; Hajime Uno; Andrew S Levey; Lesley A Inker; Marc A Pfeffer; Scott D Solomon Journal: Am Heart J Date: 2011-08-09 Impact factor: 4.749
Authors: Kati Kaartinen; Ulla Hemmilä; Kaija Salmela; Anne Räisänen-Sokolowski; Timo Kouri; Satu Mäkelä Journal: J Am Soc Nephrol Date: 2014-01-23 Impact factor: 10.121
Authors: D J de Jong; K J Assmann; R A De Abreu; L A Monnens; F J van Liebergen; H B Dijkman; F T Huysmans Journal: J Urol Date: 1996-11 Impact factor: 7.450
Authors: Vidar O Edvardsson; David S Goldfarb; John C Lieske; Lada Beara-Lasic; Franca Anglani; Dawn S Milliner; Runolfur Palsson Journal: Pediatr Nephrol Date: 2013-01-20 Impact factor: 3.714
Authors: Jennifer Li; Meena Shingde; Brian J Nankivell; Michel C Tchan; Bhadran Bose; Jeremy R Chapman; Kathy Kable; Sul Ki Kim; Mirna Vucak-Dzumhur; Germaine Wong; Gopala K Rangan Journal: Kidney Int Rep Date: 2019-05-07